https://www.selleckchem.com/products/hs94.html
orrhage. Onset to treatment time was an independent predictor of ENI at 7 days after thrombolysis in AIS patients.INTRODUCTION Intravenous thrombolytic therapy with recombinant tissue type plasminogen activator (IV-tPA) is the first-line treatment option for acute ischemic stroke (AIS). The tPA exclusion criteria, defined decades ago, require updates as new technologies emerge. Transcatheter aortic valve replacement (TAVR), which has begun to replace open surgery, poses a risk for acute stroke and falls outside of prior tPA guidelines. CAS
Like
Comment
Share
